Dr. Elizabeth A Lawson, MD

Claim this profile

Massachusetts General Hospital, Neuroendocrine Unit

Studies Obesity
Studies Oxytocin
3 reported clinical trials
5 drugs studied

Affiliated Hospitals

Image of trial facility.
Massachusetts General Hospital Neuroendocrine Unit
Image of trial facility.
Massachusetts General Hospital

Clinical Trials Elizabeth A Lawson, MD is currently running

Image of trial facility.

Oxytocin

for Adolescent Obesity

This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in youths with obesity, ages 12-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (1 spray per nostril, 4 times per day) for 12 weeks. Study visits include screening to determine eligibility, 2-part main study visits at baseline, week 8, and week 12, and safety check-in visits at weeks 1, and 4; phone calls at weeks 2, 6, and 10, with a safety follow-up visit 6 weeks after the last dose of study drug. Study procedures include appetite, behavioral, metabolic, and endocrine assessments.
Recruiting0 awards Phase 23 criteria
Image of trial facility.

Intranasal Oxytocin

for Central Diabetes Insipidus

This is a randomized, double-blind, placebo-controlled crossover pilot study of single-dose intranasal oxytocin (6 IU and 24 IU) vs. placebo in adult men and women (aged 18 years and above) with arginine-vasopressin deficiency to evaluate the effect of oxytocin on anxiety, depression, and socioemotional functioning (Part A), with an optional randomized, double-blind, placebo-controlled 2-week repeated dose substudy of intranasal oxytocin 6 IU or placebo (Part B). Following a screening visit to determine eligibility, participants will return for three main study visits in Part A. During the main study visits, study participants will receive either oxytocin or placebo, followed by assessments of emotional behavior. In Part A, thirty participants will be equally randomized to one of six possible groups: 1. 6 IU oxytocin - 24 IU oxytocin - placebo 2. 6 IU oxytocin - placebo - 24 IU oxytocin 3. 24 IU oxytocin - 6 IU oxytocin - placebo 4. 24 IU oxytocin - placebo - 6 IU oxytocin 5. placebo - 6 IU oxytocin - 24 IU oxytocin 6. placebo - 24 IU oxytocin - 6 IU oxytocin Following completion of the Part A crossover portion of the study, in Part B participants may also choose to continue participation in an optional, randomized, double-blind, placebo-controlled substudy of intranasal oxytocin 6 IU or placebo three times a day for two weeks, followed by assessments of emotional behavior.
Recruiting0 awards Phase 13 criteria

More about Elizabeth A Lawson, MD

Clinical Trial Related4 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Elizabeth A Lawson, MD has experience with
  • Oxytocin Nasal Spray
  • Placebo
  • Intranasal Oxytocin Spray
  • Intranasal Oxytocin Spray
  • Intranasal Placebo Spray
Breakdown of trials Elizabeth A Lawson, MD has run
Autism Spectrum Disorder

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Elizabeth A Lawson, MD specialize in?
Is Elizabeth A Lawson, MD currently recruiting for clinical trials?
Are there any treatments that Elizabeth A Lawson, MD has studied deeply?
What is the best way to schedule an appointment with Elizabeth A Lawson, MD?
What is the office address of Elizabeth A Lawson, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security